| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GLAZER CAPITAL, LLC | 6.4% | $24,247,147 | 3,012,068 | Glazer Capital, LLC | 30 Jun 2025 | |||
| Invus Global Management, LLC | 4.9% | $2,966,647 | 1,991,038 | Raymond Debbane | 31 Dec 2024 | |||
| Vida Ventures GP III, L.L.C. | 3.5% | -43% | $3,939,863 | -$2,909,357 | 1,634,798 | -42% | Vida Ventures GP III, L.L.C. | 10 Jun 2025 |
As of 30 Sep 2025, 1 institutional investors reported holding 565 shares of Vigil Neuroscience, Inc. - Common Stock (VIGL). This represents 0% of the company’s total 46,631,948 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 565 | $4,548 | -$265,756,902 | $8.05 | 1 |
| 2025 Q2 | 33,429,162 | $265,762,648 | +$134,567,126 | $7.95 | 78 |
| 2025 Q1 | 25,028,008 | $44,548,726 | +$4,459,745 | $1.78 | 50 |
| 2024 Q4 | 22,613,677 | $38,441,999 | -$6,722,259 | $1.70 | 51 |
| 2024 Q3 | 27,719,278 | $94,246,371 | -$2,955,690 | $3.40 | 51 |
| 2024 Q2 | 26,133,344 | $104,533,722 | -$743,555 | $4.00 | 57 |
| 2024 Q1 | 26,485,301 | $90,315,111 | +$5,966,229 | $3.41 | 51 |
| 2023 Q4 | 24,962,629 | $84,374,332 | -$4,329,880 | $3.38 | 46 |
| 2023 Q3 | 25,543,568 | $137,680,559 | -$1,479,064 | $5.39 | 44 |
| 2023 Q2 | 25,748,575 | $242,076,375 | +$6,248,476 | $9.40 | 46 |
| 2023 Q1 | 25,017,871 | $244,924,293 | +$901,731 | $9.79 | 38 |
| 2022 Q4 | 24,983,871 | $312,298,857 | +$2,449,000 | $12.50 | 35 |
| 2022 Q3 | 24,555,195 | $222,707,000 | +$65,545,435 | $9.10 | 30 |
| 2022 Q2 | 17,327,001 | $44,583,000 | -$2,575,505 | $2.58 | 29 |
| 2022 Q1 | 17,858,901 | $125,095,000 | +$125,078,173 | $7.03 | 46 |